Results

1–4 of 4 results for Peter J. Kertes

Canadian Treat-and-Extend Trial With Ranibizumab in nAMD Patients: CANTREAT 36-Month Extension Results
Peter J. Kertes, MD, FRCS(C)
Annual Meeting Talks
2020
Geographic Atrophy in the Canadian Treat and Extend Trial With Ranibizumab in nAMD Patients: CANTREAT Study 24-Month Results
Peter J. Kertes, MD, FRCS(C)
Annual Meeting Talks
2019
Canadian Treat-and-Extend Analysis Trial With Ranibizumab in Patients With Neovascular AMD: CANTREAT Study 1-Year Results
Peter J. Kertes, MD, FRCS(C)
Annual Meeting Talks
2018
Canadian Treat-and-Extend Analysis Trial with Ranibizumab in Patients With Neovascular AMD: CANTREAT Study 1-Year Results
Peter J. Kertes, MD, FRCS(C)
Updates from the Field
2018